by admin | May 15, 2019 | 2019, News
Total revenues of approximately $9.4 million for the first quarter of 2019 compared to $6.8 million for the first quarter of 2018.Net income of $6.6 million, or $0.51 per share, and non-GAAP Adjusted net income of $7.4 million, or $0.57 per share for the first quarter...
by admin | Mar 29, 2019 | 2018, News
Total revenues of approximately $26.0 million for the fiscal year 2018 compared to $37.5 million for the fiscal year 2017.For the fiscal year 2018 net income attributable to SWK Stockholders of $6.2 million, or $0.47 per share, and non-GAAP adjusted net income...
by admin | Feb 21, 2019 | Case Study
In December 2012 SWK acquired a limited partnership interest in Holmdel Pharmaceuticals Holmdel subsequently acquired the U.S. marketing authorization rights to InnoPran XL, a non-selective beta blocker using dosing technology to provide maximum active ingredient...
by admin | Feb 21, 2019 | Case Study
Narcan is the only FDA approved, intranasal Naloxone product for the treatment of opioid overdose Narcan is appropriately priced with revenue growth due to a differentiated nasal dosing and expanded distribution, not price hikes Opiant is a publicly traded drug...
by admin | Feb 21, 2019 | Case Study
Orametrix was a Dallas-based, digital orthodontic company providing robotically bent and highly-accurate wire arches for braces In late 2016 the company approached SWK in need of funding to expand into the clear aligner market Upon completion of this project,...
